Clinical trials: Sorafenib, open to volunteers
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Osteosarcoma
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Prospective, open, interventional, randomized, non-commercial trial
- Trial name
- Dragonfly (NCT07787429)
- Testing
- Mifamurtide, Sorafenib
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Anna Raciborska
Neuroblastoma
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard…
- Trial name
- PEDS-PLAN (NCT02559778)
- Testing
- Ceritinib, dasatinib, sorafenib
- Where
- 28 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Giselle Sholler
Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML
This is a prospective, single-center, observational study to evaluate the efficacy and safety of salvage haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) combined with post-transplant relapse…
- Conditions
- Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, AML, Relapsed/Refractory
- Trial name
- NCT07572695
- Testing
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT), Post-transplant Maintenance Therapy
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Refractory Solid Tumor, Hepatocellular Carcinoma
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent…
- Conditions
- Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer
- Trial name
- NCT05468359
- Testing
- Atezolizumab, Sorafenib, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- St. Jude Children's Research Hospital
AML, MDS
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
This study is a prospective, multicenter, open-label umbrella clinical study planned to enroll 126 subjects with acute myeloid leukemia/myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT06972641
- Testing
- Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Ruijin Hospital
Hepatocellular Carcinoma
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
It is estimated that over 50% of HCC cases worldwide are related to chronic HBV. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia.
- Trial name
- NCT03899428
- Testing
- Durvalumab, Sorafenib, Lenvatinib
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Humanity & Health Medical Group Limited
Ovarian Cancer
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly…
- Trial name
- NCT06437353
- Testing
- Paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Anhui Provincial Cancer Hospital
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
- Trial name
- SoraGVL (NCT06532084)
- Testing
- Sorafenib
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Leukemia, Acute, MDS
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
- Trial name
- NCT03680677
- Testing
- Bone Marrow or Peripheral Blood Graft (BMT), Cancer-directed Therapy or Best Supportive Care, Frailty Assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
AML, Adult
Venetoclax-Decitabine in Untreated Elderly/Unfit AML
Acute myeloid leukemia (AML) is a highly fatal malignancy in China, with particularly poor outcomes in elderly patients. Low-intensity regimens yield low remission rates, and median overall survival (OS) typically remains under…
- Trial name
- NCT07117422
- Testing
- VEN + DEC
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The Second Hospital of Hebei Medical University
Hepatocellular Carcinoma, Liver Cancer
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma
The goal of this clinical trial is to learn how well BGB-B2033 works and how safe it is in people with hepatocellular carcinoma (HCC) who have previously received up to two treatments that included programmed cell death protein 1…
- Trial name
- NCT07836530
- Testing
- BGB-B2033, Lenvatinib, Sorafenib
- Volunteers
- 492 people
- Sponsor
- BeOne Medicines
Advanced Hepatocellular Carcinoma (HCC)
Phase 2 Study of WGI-0301 for Advanced HCC
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have…
- Trial name
- NCT06309485
- Testing
- WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 60 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital
Liver Transplant; Complications, Hepatocarcinoma
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety…
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Trial name
- NCT06041490
- Testing
- multi-kinase inhibitors in combination with bevacizumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking Union Medical College Hospital
High Risk Acute Lymphoblastic Leukemia
Blinatumomab Maintenance After Allo-HSCT
To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.
- Trial name
- NCT06438796
- Testing
- Blinatumomab
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Hepatoblastoma
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
Hepatoblastoma is the most common malignant liver tumor in infants and preschool children, comprising 65% of pediatric liver malignancies in those under 15, with its incidence on the rise in recent years [1].
- Trial name
- NCT07300449
- Testing
- Very low-risk group, Low-risk group, Intermediate-risk group
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Type 1 Diabetes
Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.
- Trial name
- NCT06227221
- Testing
- Sorafenib
- Volunteers
- 10 people
- Sponsor
- Second Xiangya Hospital of Central South University
Kidney Cancer, Renal Cell Carcinoma Metastatic
TDM for Optimized Outcome in Patients With mRCC.
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity, Drug Side Effect
- Trial name
- NCT04659343
- Testing
- Measurement of concentration of active metabolite in cancer treatment.
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Niels Fristrup